System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Cristiano Caruso is an expert in Immunology at Agostino Gemelli University Polyclinic (Italy). As of October 2026, ScienceLeadR ranks Cristiano Caruso in the top 1% of experts worldwide for Asthma, Hypersensitivity and Lung Diseases, Obstructive. Cristiano Caruso has authored 175 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 3 of them ongoing. SLR score: 747 (community average: 125). How the SLR is computed.

LeadR Profile

Cristiano Caruso Agostino Gemelli University Polyclinic Italy
747 ScienceLeadR Reputation 747

Unlock

Register Login
Network Map

Immunology

Subspecialties: Pulmonology - Pharmacy - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2015 - 2026
Source: PubMed

Agostino Gemelli University Polyclinic

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 175

Citations

Citations: 3 059 1st author: 19 Last author: 11 Unique author: 0

Main journals

World Allergy Organ J 12
Allergy 10
J Allergy Clin Immunol 10
J Allergy Clin Immunol Pract 10
Dig Liver Dis 6

Best Journals

Am J Respir Crit Care Med 1
Lancet 1
Lancet Respir Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Letter: Sinonasal Microbiota: The Immunological Link Between Eosinophilic Oesophagitis and Chronic Rhinosunisitis?
PMID 42817033 — pharmacology, therapeutics, microbiota		Aliment Pharmacol Ther20260
Adherence To Inhaled Treatment Is Associated With Better Disease Control And Quality Of Life In Mild-To-Moderate Asthma.
PMID 42660367 — quality of life, therapeutics, asthma, smoking		Respir Med20260
Staphylococcus Aureus Toxins and Asthma: Pathophysiological Mechanisms, Clinical Relevance, and Therapeutic Implications in the Biologics Era.
PMID 42646747 — cells, superantigens, extracellular vesicles, staphylococcus, enterotoxins, eosinophils, allergens, biofilms, immunity, staphylococcus aureus, therapeutics, asthma, t-lymphocytes, microbiota, dermatitis, atopic		Toxins (Basel)20261
A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis.
PMID 42571238 — blood, adrenal cortex hormones, eosinophils, therapeutics, asthma		World Allergy Organ J20260
Trajectories in Oxidative Stress and Corticosteroids Insensitivity in Patient with High Risk of Severe Asthma: Use of FeNO as Biomarker of Respiratory Epithelial Barrier Distress.
PMID 42514269 — stress, physiological, adrenal cortex hormones, oxidative stress, biomarkers, therapeutics, asthma, steroids, immunology		Life (Basel)20260

Clinical Studies 13

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 7
N/A 2
Phase 2 2
Phase 4 2

By status:

Active not recruiting 4
Completed 4
Terminated 2
Unknown 2
Recruiting 1

By type:

Interventional 11
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 12

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An open label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma
2024-512113-41-00 — maintenance, therapeutics, asthma		Phase 3Active not recruiting2024
Dose Range Finding Study to Access Efficacy and Safety of Tozorakimab in Adults with Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroids
2024-519116-14-00 — safety, adrenal cortex hormones, therapeutics, asthma		Phase 2Active not recruiting2025
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma
2024-515162-13-00 — safety, adrenal cortex hormones, therapeutics, asthma		Phase 3Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS